ACTRN12618000247279已完成1 期
A single dose, randomized, blinded, pharmacokinetic study of a test formulation of 1 x 10 mg alitretinoin capsule in a 2 way crossover comparison against the innovator 1 x 10 mg alitretinoin capsule conducted under fed conditions in healthy male volunteers.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- Male
入选标准
- •Healthy males
- •Aged between 18 and 55 years
- •Non-smoker
- •BMI greater than or equal to 19 and less than 30 inclusive
- •Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
- •Drug free as determined by urine drug testing
- •Able to comply with the study restrictions
- •Able to provide written informed consent
排除标准
- •History of recent recurrent attacks of bronchitis, asthma or migraine headaches
- •Concomitant drug therapy of any kind
- •Received an investigational compound or drug known to induce or inhibit liver enzymes within 60 days of the start of the study
- •History of depression or other mental illness, or a history of epilepsy or seizures
- •History of conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
- •History of alcohol or drug abuse or dependency
- •Sensitivities to Vitamin A or food such as liver
- •Participation in a drug study within 60 days of the start of the study or undertaking to donate blood within 60 days after the completion of the study
- •Sensitivities to alitretinoin, its excipients or any other retinoids
- •Individuals for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk
研究者
相似试验
已完成
1 期
Comparative assessment of the absorption of a generic formulation of 75 mg 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2- naphthalenyl) ethenyl] benzoic acid capsule against the innovator 75 mg 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2- naphthalenyl) ethenyl] benzoic acid capsule conducted under fed conditions in healthy volunteers.4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2- naphthalenyl) ethenyl] benzoic acid is a member of a subclass of retinoids. It is indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL).Cancer - Lymphoma (non Hodgkin's lymphoma) - Low grade lymphomaACTRN12620000825954Zenith Technology Corporation Limited57
已完成
1 期
Comparative assessment of the absorption of a test formulation of 1 x 30 mg alitretinoin capsule against the innovator 1 x 30 mg alitretinoin capsule conducted under fed conditions in healthy male volunteers.Bioequivalence study conducted in healthy volunteers comparing a formulation of alitretinoin with no health condition or problem studied. Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, alitretinoin is a medicine that is used to treat severe chronic eczema that is unresponsive to treatment with potent topical corticosteroids.Bioequivalence study conducted in healthy volunteers comparing a formulation of alitretinoin with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, alitretinoin is a medicine that is used to treat severe chronic eczema that is unresponsive to treatment with potent topical corticosteroids.Skin - Dermatological conditionsACTRN12616001221448Zenith Technology Corp Ltd30
已完成
1 期
Comparative assessment of the absorption of a generic formulation of N-acetyl-5-methoxytryptamine prolonged release tablet against the innovator N-acetyl-5-methoxytryptamine prolonged release tablet conducted under fasting conditions in healthy male and female volunteers.-acetyl-5-methoxytryptamine is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.N-acetyl-5-methoxytryptamine is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.Mental Health - Other mental health disordersNeurological - Other neurological disordersACTRN12622000956707Zenith Technology Corporation Limited28
已完成
1 期
Comparative assessment of the absorption of a generic formulation of 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate extended release tablet against the innovator 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate extended release tablet conducted under fasting conditions in healthy male and female volunteers5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate is indicated for the treatment of hypertension.Cardiovascular - HypertensionACTRN12622001178730Zenith Technology Corporation Limited36
已完成
1 期
Comparative assessment of the absorption of a generic formulation of N-acetyl-5-methoxytryptamine prolonged release tablet against the innovator N-acetyl-5-methoxytryptamine prolonged release tablet conducted under fed conditions in healthy male and female volunteers.-acetyl-5-methoxytryptamine is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.N-acetyl-5-methoxytryptamine is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.Mental Health - Other mental health disordersNeurological - Other neurological disordersACTRN12622000966796Zenith Technology Corporation Limited28